

Matthias Scheffler

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6717105/publications.pdf>

Version: 2024-02-01

81
papers

2,883
citations

212478

28
h-index

198040

52
g-index

83
all docs

83
docs citations

83
times ranked

4791
citing authors

#	ARTICLE	IF	CITATIONS
1	Comprehensive Analysis of TP53 and KEAP1 Mutations and Their Impact on Survival in Localized- and Advanced-Stage NSCLC. <i>Journal of Thoracic Oncology</i> , 2022, 17, 76-88.	0.5	37
2	Reproducibility of dynamic contrast enhanced MRI derived transfer coefficient K _{trans} in lung cancer. <i>PLoS ONE</i> , 2022, 17, e0265056.	1.1	3
3	Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations. <i>European Journal of Cancer</i> , 2022, 167, 142-148.	1.3	32
4	Rebiopsy in advanced non-small cell lung cancer, clinical relevance and prognostic implications. <i>Lung Cancer</i> , 2022, 168, 10-20.	0.9	6
5	Crizotinib in <i>ROS1</i> -rearranged lung cancer (EUCROSS): Updated overall survival.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9078-9078.	0.8	2
6	Screening of FGFR patients for FGFR directed clinical trials in Network Genomic Medicine (NGM): Real-world data.. <i>Journal of Clinical Oncology</i> , 2022, 40, e21013-e21013.	0.8	0
7	Metastatic patterns plus clinical and molecular characteristics of <i>ROS1</i> aberrations in non-small cell lung cancer patients without rearrangements.. <i>Journal of Clinical Oncology</i> , 2022, 40, e21117-e21117.	0.8	0
8	Genetic Heterogeneity of MET-Aberrant NSCLC and Its Impact on the Outcome of Immunotherapy. <i>Journal of Thoracic Oncology</i> , 2021, 16, 572-582.	0.5	38
9	Treatment Monitoring of Immunotherapy and Targeted Therapy Using ¹⁸ F-FET PET in Patients with Melanoma and Lung Cancer Brain Metastases: Initial Experiences. <i>Journal of Nuclear Medicine</i> , 2021, 62, 464-470.	2.8	25
10	Phase 1 and phase 2a, first-in-human (FIH) study, of DRP-104, a broad glutamine antagonist, in adult patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS3149-TPS3149.	0.8	11
11	<i>KEAP1</i> mutations in squamous cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, e21098-e21098.	0.8	0
12	Fully Automated MR Detection and Segmentation of Brain Metastases in Non-small Cell Lung Cancer Using Deep Learning. <i>Journal of Magnetic Resonance Imaging</i> , 2021, 54, 1608-1622.	1.9	25
13	Real-world efficacy of docetaxel plus nintedanib after chemo-immunotherapy failure in advanced pulmonary adenocarcinoma. <i>Future Oncology</i> , 2021, 17, 3965-3976.	1.1	6
14	On target: Rational approaches to KRAS inhibition for treatment of non-small cell lung carcinoma. <i>Lung Cancer</i> , 2021, 160, 152-165.	0.9	24
15	Clonal dynamics of BRAF-driven drug resistance in EGFR-mutant lung cancer. <i>Npj Precision Oncology</i> , 2021, 5, 102.	2.3	11
16	32. TREATMENT MONITORING OF IMMUNOTHERAPY AND TARGETED THERAPY USING AMINO ACID PET IN PATIENTS WITH BRAIN METASTASES. <i>Neuro-Oncology Advances</i> , 2020, 2, ii5-ii6.	0.4	1
17	Co-occurrence of targetable mutations in Non-small cell lung cancer (NSCLC) patients harboring MAP2K1 mutations. <i>Lung Cancer</i> , 2020, 144, 40-48.	0.9	9
18	Sorafenib and everolimus in patients with advanced solid tumors and KRAS-mutated NSCLC: A phase I trial with early pharmacodynamic FDG-PET assessment. <i>Cancer Medicine</i> , 2020, 9, 4991-5007.	1.3	14

#	ARTICLE	IF	CITATIONS
19	Abstract CT255: EATON: A phase I dose-escalation trial of nazartinib (EGF816) and trametinib in EGFR-mutant NSCLC. , 2020, , .		0
20	OTHR-14. TREATMENT MONITORING OF IMMUNOTHERAPY AND TARGETED THERAPY USING FET PET IN PATIENTS WITH MELANOMA AND LUNG CANCER BRAIN METASTASES: INITIAL EXPERIENCES. <i>Neuro-Oncology Advances</i> , 2019, 1, i21-i21.	0.4	0
21	Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1266-1276.	0.5	78
22	Acquired KRAS mutation and loss of low-level MET amplification after durable response to crizotinib in a patient with lung adenocarcinoma. <i>Lung Cancer</i> , 2019, 133, 20-22.	0.9	4
23	Genomic Profiling Identifies Outcome-Relevant Mechanisms of Innate and Acquired Resistance to Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Lung Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-14.	1.5	17
24	K-ras Mutation Subtypes in NSCLC and Associated Co-occurring Mutations in Other Oncogenic Pathways. <i>Journal of Thoracic Oncology</i> , 2019, 14, 606-616.	0.5	178
25	Monitoring Treatment Response to Erlotinib in EGFR-mutated Non-small-cell Lung Cancer Brain Metastases Using Serial O-(2-[18F]fluoroethyl)-L-tyrosine PET. <i>Clinical Lung Cancer</i> , 2019, 20, e148-e151.	1.1	11
26	Association of STK11/LKB1 genomic alterations with lack of benefit from the addition of pembrolizumab to platinum doublet chemotherapy in non-squamous non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 102-102.	0.8	72
27	Acquired resistance to MET inhibition in MET driven NSCLC.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9030-9030.	0.8	5
28	Treatment monitoring of immunotherapy and targeted therapy using FET PET in patients with melanoma and lung cancer brain metastases: Initial experiences.. <i>Journal of Clinical Oncology</i> , 2019, 37, e13525-e13525.	0.8	3
29	Overcoming acquired osimertinib-resistance in EGFR-mutant advanced non-small lung cancer mediated by activating BRAF V600E mutation.. <i>Journal of Clinical Oncology</i> , 2019, 37, e20682-e20682.	0.8	2
30	EATON: An open-label, multicenter, phase I dose-escalation trial of nazartinib (EGF816) and trametinib in patients with EGFR-mutant non-small cell lung cancer – preliminary data on safety and tolerability.. <i>Journal of Clinical Oncology</i> , 2019, 37, e20577-e20577.	0.8	1
31	Clinical and Pathological Characteristics of KEAP1- and NFE2L2-Mutated Non-small Cell Lung Carcinoma (NSCLC). <i>Clinical Cancer Research</i> , 2018, 24, 3087-3096.	3.2	116
32	Loss of G2032R Resistance Mutation Upon Chemotherapy Treatment Enables Successful Crizotinib Rechallenge in a Patient With ROS1-Rearranged NSCLC. <i>JCO Precision Oncology</i> , 2018, 2, 1-6.	1.5	2
33	Overcoming EGFRG724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors. <i>Nature Communications</i> , 2018, 9, 4655.	5.8	107
34	Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer. <i>Annals of Oncology</i> , 2018, 29, 2068-2075.	0.6	132
35	P2.03b-076 MAP2K1 Mutations in NSCLC: Clinical Presentation and Co-Occurrence of Additional Genetic Aberrations. <i>Journal of Thoracic Oncology</i> , 2017, 12, S982.	0.5	0
36	P2.03b-028 Improved Overall Survival Following Implementation of NGS in Routine Diagnostics of Advanced Lung Cancer in Germany: Results of the NGM. <i>Journal of Thoracic Oncology</i> , 2017, 12, S950-S951.	0.5	0

#	ARTICLE	IF	CITATIONS
37	P2.03b-036 Analysis of Potentially Targetable Mutations in 821 Patients with Squamous cell Lung Cancer Undergoing Routine NGS-Based Molecular Diagnostics. <i>Journal of Thoracic Oncology</i> , 2017, 12, S956-S957.	0.5	0
38	YI01b.02 Expectations from a Young Investigator. <i>Journal of Thoracic Oncology</i> , 2017, 12, S226-S227.	0.5	0
39	MA07.05 EUCROSS: A European Phase II Trial of Crizotinib in Advanced Adenocarcinoma of the Lung Harboring ROS1 Rearrangements - Preliminary Results. <i>Journal of Thoracic Oncology</i> , 2017, 12, S379-S380.	0.5	15
40	Economic burden of clinical trials in lung cancer in a German Comprehensive Cancer Center. <i>Lung Cancer</i> , 2017, 108, 134-139.	0.9	1
41	ALK G1269A mutation as a potential mechanism of acquired resistance to crizotinib in an ALK-rearranged inflammatory myofibroblastic tumor. <i>Npj Precision Oncology</i> , 2017, 1, 4.	2.3	30
42	Targeting Fibroblast Growth Factor Receptor 1 for Treatment of Soft-Tissue Sarcoma. <i>Clinical Cancer Research</i> , 2017, 23, 962-973.	3.2	29
43	Fibroblast kinase 1-3 inhibitor BCJ398 in patients with FGFR1 amplified squamous non-small cell lung cancer treated in a phase I study: Evaluation of tumor tissue and response at a single center.. <i>Journal of Clinical Oncology</i> , 2017, 35, e20664-e20664.	0.8	0
44	Expanded molecular routine testing for targetable mutations in non-small cell lung cancer to reveal frequent co-occurring mutations.. <i>Journal of Clinical Oncology</i> , 2017, 35, e20596-e20596.	0.8	0
45	Co-occurrence of targetable aberrations in non-small cell lung cancer patients harboring <i>MAP2K1</i> mutations.. <i>Journal of Clinical Oncology</i> , 2017, 35, e20059-e20059.	0.8	0
46	Molecular panel sequencing of pre-treatment samples to reveal mechanisms of innate resistance to 3rd generation EGFR TKI treatment in T790M-positive NSCLC patients.. <i>Journal of Clinical Oncology</i> , 2017, 35, 9041-9041.	0.8	0
47	PD-L1 expression in non-small cell lung cancer: Correlations with genetic alterations. <i>Oncotarget</i> , 2016, 5, e1131379.	2.1	94
48	Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors. <i>Clinical Cancer Research</i> , 2016, 22, 4837-4847.	3.2	223
49	Clinicopathological Characteristics of RET Rearranged Lung Cancer in European Patients. <i>Journal of Thoracic Oncology</i> , 2016, 11, 122-127.	0.5	65
50	Impact of PET/CT image reconstruction methods and liver uptake normalization strategies on quantitative image analysis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 249-258.	3.3	49
51	Genetic heterogeneity of KRAS-mutated NSCLC: Co-occurrence of potentially targetable aberrations and evolutionary background.. <i>Journal of Clinical Oncology</i> , 2016, 34, 9018-9018.	0.8	5
52	Survival following implementation of next-generation sequencing in routine diagnostics of advanced lung cancer: Results of the German Network Genomic Medicine.. <i>Journal of Clinical Oncology</i> , 2016, 34, 9085-9085.	0.8	7
53	Economic burden of clinical trials in lung cancer in a German comprehensive cancer center.. <i>Journal of Clinical Oncology</i> , 2016, 34, e18278-e18278.	0.8	0
54	Targeted Therapy for Patients with BRAF-Mutant Lung Cancer Results from the European EURAF Cohort. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1451-1457.	0.5	141

#	ARTICLE	IF	CITATIONS
55	Implementation of Amplicon Parallel Sequencing Leads to Improvement of Diagnosis and Therapy of Lung Cancer Patients. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1049-1057.	0.5	85
56	Spatial Tumor Heterogeneity in Lung Cancer with Acquired Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Resistance: Targeting High-Level MET-Amplification and EGFR T790M Mutation Occurring at Different Sites in the Same Patient. <i>Journal of Thoracic Oncology</i> , 2015, 10, e40-e43.	0.5	33
57	Modeling Tumor Dynamics and Overall Survival in Advanced Non-Small-Cell Lung Cancer Treated with Erlotinib. <i>Journal of Thoracic Oncology</i> , 2015, 10, 84-92.	0.5	12
58	Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors. <i>Oncologist</i> , 2015, 20, 1167-1174.	1.9	59
59	A Modeling and Simulation Framework for Adverse Events in Erlotinib-Treated Non-Small-Cell Lung Cancer Patients. <i>AAPS Journal</i> , 2015, 17, 1483-1491.	2.2	7
60	KEAP1-mutations in patients with non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 8097-8097.	0.8	1
61	Clinical and molecular characteristics of non-small cell lung cancer in patients harboring CTNNB1 mutations.. <i>Journal of Clinical Oncology</i> , 2015, 33, 8098-8098.	0.8	1
62	The network genomic medicine cost reimbursement model for implementation of comprehensive lung cancer genotyping in clinical routine.. <i>Journal of Clinical Oncology</i> , 2015, 33, e12556-e12556.	0.8	1
63	PIK3CA mutations in non-small cell lung cancer (NSCLC): Genetic heterogeneity, prognostic impact and incidence of prior malignancies. <i>Oncotarget</i> , 2015, 6, 1315-1326.	0.8	105
64	ROS1 rearrangements in lung adenocarcinoma: prognostic impact, therapeutic options and genetic variability. <i>Oncotarget</i> , 2015, 6, 10577-10585.	0.8	85
65	Genetic variability and clinical presentation of patients with non-small cell lung cancer (NSCLC) harboring MET-amplifications.. <i>Journal of Clinical Oncology</i> , 2015, 33, 8088-8088.	0.8	0
66	SORAVE: A phase I trial to evaluate safety and efficacy of combination therapy with everolimus and sorafenib.. <i>Journal of Clinical Oncology</i> , 2015, 33, 2550-2550.	0.8	1
67	ROS1 rearrangement in non-small cell lung cancer (NSCLC): Prognostic and predicitive impact and genetic variability.. <i>Journal of Clinical Oncology</i> , 2015, 33, 8066-8066.	0.8	0
68	Abstract 752: Elucidating the mechanisms of acquired resistance in lung adenocarcinomas. , 2015, , .		0
69	Cell-Autonomous and Non-Cell-Autonomous Mechanisms of Transformation by Amplified FGFR1 in Lung Cancer. <i>Cancer Discovery</i> , 2014, 4, 246-257.	7.7	93
70	Abstract 956: Elucidating the mechanisms of acquired resistance in lung adenocarcinomas. , 2014, , .		0
71	Prognostic Impact of [18F]Fluorothymidine and [18F]Fluoro-D-Glucose Baseline Uptakes in Patients with Lung Cancer Treated First-Line with Erlotinib. <i>PLoS ONE</i> , 2013, 8, e53081.	1.1	36
72	Tumor Lesion Glycolysis and Tumor Lesion Proliferation for Response Prediction and Prognostic Differentiation in Patients With Advanced Non-Small Cell Lung Cancer Treated With Erlotinib. <i>Clinical Nuclear Medicine</i> , 2012, 37, 1058-1064.	0.7	47

#	ARTICLE	IF	CITATIONS
73	Monitoring reversible and irreversible EGFR inhibition with erlotinib and afatinib in a patient with EGFR-mutated non-small cell lung cancer (NSCLC) using sequential [¹⁸ F]fluorothymidine (FLT-)PET. Lung Cancer, 2012, 77, 617-620.	0.9	14
74	Predictive value of early and late residual ¹⁸ F-fluorodeoxyglucose and ¹⁸ F-fluorothymidine uptake using different SUV measurements in patients with non-small-cell lung cancer treated with erlotinib. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 1117-1127.	3.3	43
75	Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors. Clinical Pharmacokinetics, 2011, 50, 371-403.	1.6	95
76	Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors. Clinical Pharmacokinetics, 2011, 50, 551-603.	1.6	163
77	Early Prediction of Nonprogression in Advanced Non-Small-Cell Lung Cancer Treated With Erlotinib By Using [¹⁸ F]Fluorodeoxyglucose and [¹⁸ F]Fluorothymidine Positron Emission Tomography. Journal of Clinical Oncology, 2011, 29, 1701-1708.	0.8	170
78	Benchmarking of Mutation Diagnostics in Clinical Lung Cancer Specimens. PLoS ONE, 2011, 6, e19601.	1.1	107
79	Reply to M. Quintela-Fandino et al. Journal of Clinical Oncology, 2011, 29, 3718-3719.	0.8	0
80	Quantitative Analysis of Response to Treatment with Erlotinib in Advanced Non-Small Cell Lung Cancer Using ¹⁸ F-FDG and ³ H-Deoxy- ³ H- ¹⁸ F-Fluorothymidine PET. Journal of Nuclear Medicine, 2011, 52, 1871-1877.	2.8	65
81	Osteoblastic Response in Patients with Non-small Cell Lung Cancer with Activating EGFR Mutations and Bone Metastases during Treatment with EGFR Kinase Inhibitors. Journal of Thoracic Oncology, 2010, 5, 407-409.	0.5	22